Xcout IntelCureGenetics
CureGenetics is a biotechnology company headquartered in Suzhou, China, focused on the development of gene and cutting-edge medical therapies.
Subscribe to see CureGenetics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CureGenetics at a glance
CureGenetics is a healthcare company headquartered in China. Its most recent funding round, Series A, raised $17M in August 2018. Xcout tracks 6 named people at CureGenetics, including Dr. Yuanyuan Xu (Chairman & CEO).
CureGenetics leadership
- Dr. Yuanyuan XuChairman & CEO
- Dr. Shawn HeChief Scientific Officer
- Dr. Yanni LinCo-founder & Chief Scientist
- Grace HeSVP，Head of Clinical Development
- Dr. Lin ZhuVP, Head of Preclinical Development
- Dr. Lei ZhaoED, Head of AAV Discovery
CureGenetics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $17M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
CureGenetics competitors
A few of CureGenetics's closest competitors — see the full list of competitors and alternatives →
Belief BioMed Inc. is a globally innovative biotechnology company that integrates the development, manufacturing, and clinical application of gene therapy products. The company operates research centers, manufacturing facilities, and offices across multiple cities in China as well as the United States. Its primary operations are rooted in Shanghai, China.
GEn1E Lifesciences Inc. is a clinical-stage, Phase 2 biotechnology research company based in Palo Alto, California, focused on accelerating novel precision therapies.
GenEdit is a South San Francisco, California-based startup developing alternative methods of delivering gene-based and CRISPR-based medicines.
EdiGene is a clinical-stage biotechnology company founded in 2015 that focuses on translating gene-editing technologies into therapeutic products. Headquartered in Beijing, China, the company also operates research and office facilities in locations such as Shanghai, Guangzhou, and the United States.
KiraGen Bio is a Boston-based biotechnology company pioneering the development of AI-driven, multiplex gene-edited CAR-T cell therapies designed to target and block tumor suppression.
Yaotang (Shanghai) Biotechnology Co., Ltd. is a high-tech biotechnology company focused on developing mRNA drugs and gene editing treatments. The company combines in vivo mRNA delivery technology with gene editing to target hereditary and cardiovascular diseases.
Get CureGenetics's news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on CureGenetics in Xcout Intel
- 6 named people with titles, LinkedIn and board committees
- 1 funding round with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access